

02-18-00

Cap 1614 #5

PATENT

247/164

3/24/00

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**Applicant:**

Joel B. Epstein

Serial No.: 09/433,418**Filed:** November 4, 1999**For:** TOPICAL AZATHIOPRINE FOR
THE TREATMENT OF ORAL
AUTOIMMUNE DISEASES**Group Art Unit:** 1614**Examiner:** Not Yet AssignedFEB 23 2000
TECH CENTER 1600/2**INFORMATION DISCLOSURE STATEMENT**Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Pursuant to 37 CFR 1.97-98, Applicant here submits disclosure of information which may be deemed by the Examiner to be relevant to the examination of the present application. This submission is not to be construed as an admission that the cited information is material to patentability or qualifies as prior art under the provisions of the patent laws and regulations, and is not a representation that a search has been made. The Examiner is requested to undertake an independent search in connection with this application.

CERTIFICATE OF MAILING
 (37 C.F.R. §1.10)

I hereby certify that this paper (along with any referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as 'Express Mail Post Office To Addressee' in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

EL473933945US

Express Mail Label No.

February 17, 2000

Date of Deposit

Shawn Poindexter

Name of Person Mailing Paper

Shawn Poindexter

Signature of Person Mailing Paper

The documents are listed in the accompanying PTO-1449 form. Copies of the cited references are enclosed. The Examiner is requested to review the cited documents in their entirety in order to reach an independent assessment of relevance or materiality to patentability.

Applicant notes that one of the references, denoted reference AZ in the accompanying PTO-Form 1449, is not in the English language. Reference AZ is discussed at page 8 in the specification of the present application. Briefly, the reference discusses the treatment of patients suffering from parodontitis with a 1% suspension of azathioprine in a 1% dimexid solution. The authors report good results and an absence of side effects associated with the treatment.

Applicant wishes to notify the Examiner that Applicant's reference number for this application has been changed from 244/023 to 247/164. Applicant requests that the Examiner use this new number henceforth in connection with this application, and requests the Examiner's assistance in amending the records in the Patent Office associated with the present application to reflect this change.

Because a first Office Action has not issued in this application, applicants here request consideration of the cited information pursuant to 37 CFR 1.97(b), and no fee is believed to be due in connection with the filing of this Information Disclosure Statement. Nonetheless, should the Examiner determine that a fee is required, the Commissioner is hereby authorized to charge any further fee required by this submission to Deposit Account No. 12-2475.


Favorable consideration of the present application in view of these references of record is respectfully requested.

Respectfully submitted,

LYON & LYON LLP

Dated: February 17, 2000

By:

A handwritten signature in cursive script, reading "Charles M. Doyle", is written over a horizontal line.

Charles M. Doyle

Reg. No. 39,175

Attorneys for Applicants

633 West Fifth Street, Suite 4700
Los Angeles, California 90071-2066
(213) 489-1600